These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1217 related articles for article (PubMed ID: 32224144)

  • 1. Haploidentical stem cell transplant with post-transplantation cyclophosphamide and mini-dose methotrexate in children.
    Medina D; Estacio M; Rosales M; Manzi E
    Hematol Oncol Stem Cell Ther; 2020 Dec; 13(4):208-213. PubMed ID: 32224144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
    Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO
    Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
    Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-transplantation Cyclophosphamide-based Graft-versus-host-disease Prophylaxis Compared to Methotrexate-cyclosporine a in Matched-related Allogeneic Hematopoietic Stem Cell Transplantation.
    Shouman MT; Mansour OM; El Gammal MM; Abdel-Fattah RM; Samra MA; Elhaddad AM; Maher MA; Mahmoud HK
    Hematol Oncol Stem Cell Ther; 2023 May; 16(4):379-387. PubMed ID: 37363983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility and Outcome of Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant High-Dose Cyclophosphamide for Children and Adolescents with Hematologic Malignancies: An AIEOP-GITMO Retrospective Multicenter Study.
    Berger M; Lanino E; Cesaro S; Zecca M; Vassallo E; Faraci M; De Bortoli M; Barat V; Prete A; Fagioli F
    Biol Blood Marrow Transplant; 2016 May; 22(5):902-9. PubMed ID: 26860636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.
    Alousi AM; Brammer JE; Saliba RM; Andersson B; Popat U; Hosing C; Jones R; Shpall EJ; Khouri I; Qazilbash M; Nieto Y; Shah N; Ahmed S; Oran B; Al Atrash G; Ciurea S; Kebriaei P; Chen J; Rondon G; Champlin RE
    Biol Blood Marrow Transplant; 2015 May; 21(5):906-12. PubMed ID: 25667989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced-toxicity conditioning regimen with low dose post-transplantation cyclophosphamide and low-dose anti-thymocyte globulin as graft-versus-host disease prophylaxis for haploidentical stem cell transplantation in older patients.
    Ye P; Wu M; Cao J; Pei R; Yuan J; Zhuang H; Fang Y; Lu Y
    Ann Hematol; 2024 Aug; 103(8):3135-3143. PubMed ID: 38809457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation.
    Duléry R; Bastos J; Paviglianiti A; Malard F; Brissot E; Battipaglia G; Médiavilla C; Giannotti F; Banet A; de Wyngaert ZV; Ledraa T; Belhocine R; Sestili S; Adaeva R; Lapusan S; Isnard F; Legrand O; Vekhoff A; Rubio MT; Ruggeri A; Mohty M
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1407-1415. PubMed ID: 30871978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-Transplant Cyclophosphamide as Sole Graft-versus-Host Disease Prophylaxis Is Feasible in Patients Undergoing Peripheral Blood Stem Cell Transplantation for Severe Aplastic Anemia Using Matched Sibling Donors.
    George B; Pn N; Devasia AJ; Kulkarni U; Korula A; Lakshmi KM; Abraham A; Srivastava A; Mathews V
    Biol Blood Marrow Transplant; 2018 Mar; 24(3):494-500. PubMed ID: 29100905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies.
    Law AD; Salas MQ; Lam W; Michelis FV; Thyagu S; Kim DDH; Lipton JH; Kumar R; Messner H; Viswabandya A
    Biol Blood Marrow Transplant; 2018 Nov; 24(11):2259-2264. PubMed ID: 30009980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation.
    Kwon M; Bailén R; Pascual-Cascón MJ; Gallardo-Morillo AI; García Sola A; Balsalobre P; Solán L; Dorado N; Muñoz C; Serrano D; Martínez-Laperche C; Buño I; Anguita J; Díez-Martin JL
    Blood Adv; 2019 Nov; 3(21):3351-3359. PubMed ID: 31698447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation from sibling and unrelated donors in patients with acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Nagler A; Labopin M; Swoboda R; Schroeder T; Hamladji RM; Griskevicius L; Salmenniemi U; Rambaldi A; Mielke S; Kulagin A; Passweg J; Luft T; Gedde-Dahl T; Forcade E; Helbig G; Stelljes M; Castilla-Llorente C; Spyridonidis A; Brissot E; Ciceri F; Mohty M
    Bone Marrow Transplant; 2024 Jul; 59(7):1012-1021. PubMed ID: 38615143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Tapering of Cyclosporine Is Feasible in Haploidentical Stem Cell Transplantation: A Single Center Experience.
    Yaman S; Başci S; Bozan E; Seçilmiş S; Candir BA; Yiğenoğlu TN; Çakar MK; Dal MS; Altuntaş F
    Clin Transplant; 2024 Jun; 38(6):e15376. PubMed ID: 39031699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus Reactivations in Allogeneic Hematopoietic Stem Cell Transplantation from HLA-Matched and Haploidentical Donors with Post-Transplantation Cyclophosphamide.
    Chorão P; Henriques M; Villalba M; Montoro J; Balaguer-Roselló A; González EM; Gómez MD; Gómez I; Solves P; Santiago M; Asensi P; Lamas B; Bataller A; Granados P; Eiris J; Martínez D; Louro A; Rebollar P; Perla A; Salavert M; de la Rubia J; Sanz MÁ; Sanz J
    Transplant Cell Ther; 2024 May; 30(5):538.e1-538.e10. PubMed ID: 38331195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood for patients with hematologic malignancies: a prospective, phase II study.
    Yang J; Jiang J; Cai Y; Li S; Wan L; Zhu J; Liu H; Shao S; Bai H; Wang C; Song X
    Bone Marrow Transplant; 2019 Jul; 54(7):1049-1057. PubMed ID: 30446741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
    Ho VT; Aldridge J; Kim HT; Cutler C; Koreth J; Armand P; Antin JH; Soiffer RJ; Alyea EP
    Biol Blood Marrow Transplant; 2009 Jul; 15(7):844-50. PubMed ID: 19539216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide.
    Elmariah H; Otoukesh S; Kumar A; Ali H; Arslan S; Shouse G; Pourhassan H; Nishihori T; Faramand R; Mishra A; Khimani F; Fernandez H; Lazaryan A; Nieder M; Perez L; Liu H; Nakamura R; Pidala J; Marcucci G; Forman SJ; Anasetti C; Locke F; Bejanyan N; Al Malki MM
    Transplant Cell Ther; 2024 Feb; 30(2):229.e1-229.e11. PubMed ID: 37952648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide/Bendamustine in Pediatric and Young Adult Patients with Hematologic Malignancies.
    Katsanis E; Sapp LN; Varner N; Koza S; Stea B; Zeng Y
    Biol Blood Marrow Transplant; 2018 Oct; 24(10):2034-2039. PubMed ID: 29908231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation.
    Mehta RS; Saliba RM; Chen J; Rondon G; Hammerstrom AE; Alousi A; Qazilbash M; Bashir Q; Ahmed S; Popat U; Hosing C; Khouri I; Shpall EJ; Champlin RE; Ciurea SO
    Br J Haematol; 2016 May; 173(3):444-55. PubMed ID: 26947769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.